- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.10. | BioNexus Gene Lab Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 05.10. | Ruanyun Edai Technology Inc.: RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab | 1 | GlobeNewswire (USA) | ||
| 14.08. | BioNexus Gene Lab Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| BIONEXUS GENE LAB Aktie jetzt für 0€ handeln | |||||
| 28.07. | BioNexus Gene Lab Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 28.07. | BioNexus Gene Lab Corp.: BioNexus Advances VitaGuard Southeast Asia Rollout Following China Working Visit | 1 | GlobeNewswire (USA) | ||
| 03.07. | Eastwood Bio-Medical Canada Inc: Eastwood signs research agreement with BioNexus | 1 | Stockwatch | ||
| 05.06. | BioNexus Gene Lab Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 29.05. | BioNexus Gene Lab Corp. Calls for Malaysia-China Biotechnology Cooperation to Move Beyond Trade into Co-Development | 1 | GlobeNewswire (USA) | ||
| 15.05. | BioNexus Gene Lab Corp - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 11.03. | BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard MRD Platform | 934 | GlobeNewswire (Europe) | KUALA LUMPUR, Malaysia, March 11, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC) today announced that, in connection with its Fidelion Diagnostics Pte. Ltd ("Fidelion") transaction... ► Artikel lesen | |
| 23.02. | BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman | 324 | GlobeNewswire (Europe) | Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp.... ► Artikel lesen | |
| 02.12.25 | BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization | 265 | GlobeNewswire (Europe) | SHERIDAN, Wyo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. ("BGLC" or the "Company"), an emerging provider of precision oncology diagnostics with expanding operations across Southeast... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DRAEGERWERK | 104,20 | -0,38 % | Was jetzt entscheidend wird bei Desert Gold, Draegerwerk und Verbio | Erstellt und veröffentlicht im Auftrag von Desert Gold Ventures Inc. Starke Kursbewegungen, operative Meilensteine und veränderte Gewinnperspektiven prägen derzeit das Bild bei drei sehr unterschiedlichen... ► Artikel lesen | |
| HEARTFLOW | 59,12 | +0,03 % | Biotech Stocks At 52-Week Highs - Vaxcyte +31% On Phase 3 Results, InfuSystem, Illumina +7%, Charles River Laboratories +7%, HeartFlow +5% | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on October 5, 2026, driven by key catalysts such as encouraging clinical research data.Vaxcyte Inc. (PCVX)Vaxcyte is... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 59,48 | 0,00 % | BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance | LOUISVILLE, Ky., July 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 13,395 | +0,04 % | LifeStance Health Group, Inc.: LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook | SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen | |
| PROGYNY | 27,870 | 0,00 % | Progyny, Inc.: New Progyny Study Examines Persistent Racial and Ethnic Differences in Fertility Treatment Initiation Despite Access to Benefits | ||
| SIEMENS HEALTHINEERS | 42,890 | +0,70 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| BILLIONTOONE | 113,94 | -0,05 % | BillionToOne, Inc.: BillionToOne's Tissue-Free Northstar Response Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds | MENLO PARK, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 8,165 | 0,00 % | Needham initiates Alignment Healthcare stock rating at Hold | ||
| BETA BIONICS | 17,810 | 0,00 % | Truist reiterates Buy on Beta Bionics stock, $28 target on MINT | ||
| ADAPTHEALTH | 6,030 | 0,00 % | Morning Market Movers: Ameresco, Inno Holdings, AdaptHealth, Ibotta See Big Swings | OTTAWA (dpa-AFX) - At 7:50 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| KESTRA MEDICAL TECHNOLOGIES | 29,870 | 0,00 % | Kestra Medical Technologies, Ltd.: Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results | KIRKLAND, Wash., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported financial results... ► Artikel lesen | |
| FRESENIUS | 47,030 | +1,50 % | BERENBERG stuft Fresenius SE auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Fresenius von 50 auf 54 Euro angehoben und die Einstufung auf "Buy" belassen. Der Markt bewerte den Medizinkonzern als vom... ► Artikel lesen | |
| GENEDX | 64,61 | -0,12 % | GeneDx plans to add long-read genome sequencing to portfolio | ||
| FRESENIUS MEDICAL CARE | 41,080 | +1,18 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen |
BIONEXUS GENE LAB CORP gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 1,160 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIONEXUS GENE LAB CORP finden Sie auf Wallstreet Online.